$AMRZ

Amrize Q2 Earnings Call Highlights

Amrize (AMRZ) reported Q2 revenue up 8.6% and adjusted EBITDA up 5.8% to $986 million, with net income up 14.4%, citing demand across data centers, energy and infrastructure. Higher freight, diesel and raw-material costs pressured margins. The company raised 2026 guidance: revenue $12.5B-$12.7B and adjusted EBITDA $3.1B-$3.2B, citing pricing lag and inflation.

Original reporting
Published Aug 7, 2026, 10:04 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 8, 2026, 1:25 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Amrize Q2 Earnings Call Highlights — source image
Decision brief

The 30-second read

$AMRZNeutralMed
01

Why it matters

The key tradable update is the combination of raised 2026 revenue guidance ($12.5B-$12.7B) and adjusted EBITDA guidance ($3.1B-$3.2B), alongside quantified margin headwinds ($140M-$170M) and timing expectations (elevated costs in 3Q, better price-over-cost in 2H, positive in 4Q).

02

Market read

Traders can reprice Amrize’s margin trajectory using the disclosed guidance ranges and the explicit breakdown of volume contribution, pricing contribution, and cost headwinds by quarter.

03

What to watch

Investors may underweight the insurance-recovery lap ($55M headwind) and the 30 to 90 day pricing realization lag, which can delay margin recovery even with volume growth.

Relevance 8/10Novelty 8/10Timing: after-hours guidance update from Q2 earnings call (published 2026-08-07)

Background

Amrize’s Q2 call highlighted volume growth across cement and aggregates, but profitability pressure from freight, diesel, and raw-material costs, leading to an updated full-year outlook.

Company-level read

Ticker impact

$AMRZNeutralMedium confidence
Context

Amrize reported Q2 results and raised 2026 adjusted EBITDA guidance to $3.1B-$3.2B amid cost inflation and pricing lag.

Expected impact

Likely supports the stock on guidance, but investors may focus on the stated $140M-$170M cost headwind and weaker price-over-cost in 3Q.

Evidence & confidence

The article provides fresh, decision-relevant guidance ranges, segment pricing/volume commentary, and quantified headwinds that can drive revisions to margin expectations.

Market effects

Building materials names may see read-across from Amrize’s explicit freight, diesel, and pricing-realization lag assumptions.

North America construction and infrastructure demand sensitivity is reinforced via data center and energy project pipeline commentary.

Limited direct global linkage beyond commodity-linked cost inflation (oil-driven freight/diesel/raw materials).

Counterpoint

The raised revenue and EBITDA outlook may be offset by the magnitude of the stated cost headwind and the expectation that price-over-cost turns positive only in 4Q.

Key entities

  • Amrize

    Building materials company reporting Q2 growth and updating 2026 revenue and adjusted EBITDA guidance.

  • Jan Jenisch

    Chairman and CEO commenting on organic growth, pipeline, and market coverage.

  • Baris Oran

    CFO discussing segment pricing actions, cost headwinds, and full-year expectations.

  • Rapid Redi-Mix

    Dallas-Fort Worth concrete producer acquired in July, expected to be accretive and create synergies.

  • ASPIRE

    Operational-efficiency program expected to deliver about $80M in savings for 2026.

Related articles

$AMRZMedAI 8/10

Amrize (AMRZ) Q2 2026 Earnings Call Transcript

Amrize AG (AMRZ) reported Q2 2026 revenue of $3.49B, up 8.6%, and net income of $476M, up 14.4%, with adjusted EBITDA of $986M. Management raised fiscal 2026 revenue guidance to $12.5B-$12.7B but revised adjusted EBITDA to $3.1B-$3.2B due to oil-driven cost inflation. The company cited data center and infrastructure demand.

$AMRZMedAI 8/10

Amrize Q2 EPS misses $0.94 estimate as costs weigh on margins

Amrize (NYSE: AMRZ) reported Q2 2026 adjusted EPS of $0.88, below the $0.94 consensus estimate. Revenue rose 8.51% to $3.494 billion, beating the $3.365 billion expectation. Net income increased 14.4% to $476 million. The company raised FY2026 revenue guidance to $12.5B-$12.7B but lowered adjusted EBITDA guidance to $3.1B-$3.2B due to cost inflation.

$AMRZMed

RBC Downgrades Amrize After A Rare Q2 Miss

RBC downgraded Amrize after a rare Q2 miss and reduced guidance, citing a timing mismatch between input-cost increases and the full pass-through of surcharges and price hikes. RBC cut 2026-2028 EBITDA estimates by 4%, 6%, and 7% and EPS by 12%, 14%, and 15%, lowering its stock rating to underperform and price target to $48 from $60.